Analysts Offer Insights on Healthcare Companies: Flamel Technologies S.A. (NASDAQ: FLML), Applied Genetic Technologies (NASDAQ: AGTC) and Eagle Pharmaceuticals (NASDAQ: EGRX)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Flamel Technologies S.A. (NASDAQ: FLML), Applied Genetic Technologies (NASDAQ: AGTC) and Eagle Pharmaceuticals (NASDAQ: EGRX) with bullish sentiments.

Flamel Technologies S.A. (NASDAQ: FLML)

In a report issued on November 8, Scott Henry from Roth Capital reiterated a Buy rating on Flamel Technologies S.A. (NASDAQ: FLML), with a price target of $15. The company’s shares closed yesterday at $10.15.

According to TipRanks.com, Henry is ranked 0 out of 5 stars with an average return of -3.7% and a 32.9% success rate. Henry covers the Healthcare sector, focusing on stocks such as Acerus Pharmaceuticals Corporation, Apricus Biosciences Inc, and Alexza Pharmaceuticals.

Currently, the analyst consensus on Flamel Technologies S.A. is Strong Buy and the average price target is $35, representing a 244.8% upside.

In a report issued on November 7, SunTrust Robinson also reiterated a Buy rating on the stock with a $35 price target.
Applied Genetic Technologies (NASDAQ: AGTC)

Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Applied Genetic Technologies (NASDAQ: AGTC) on November 8 and set a price target of $15. The company’s shares closed yesterday at $9.15.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -14.1% and a 31.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., ImmunoCellular Therapeutics, and Strongbridge Biopharma Plc.

Applied Genetic Technologies has an analyst consensus of Moderate Buy.

Eagle Pharmaceuticals (NASDAQ: EGRX)

In a report released yesterday, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Eagle Pharmaceuticals (NASDAQ: EGRX). The company’s shares closed yesterday at $81.73.

Rivkind Koffler noted:

“We think top-line weakness was driven primarily by lower Bendeka royalties after Teva stocked the channel in 2Q:16. Eagle was able to beat on the bottom line due to lower than expected R&D expense, driven primarily by unexpected cost reimbursement from a supplier. Mgmt also gave an update on its $75M buyback program, indicating that it had bought back ~$32M, $18M of which occurred during 3Q:16.”

According to TipRanks.com, Koffler is a top 100 analyst with an average return of 15.1% and a 45.6% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Apricus Biosciences Inc, Sucampo Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Eagle Pharmaceuticals is Strong Buy and the average price target is $97, representing a 18.7% upside.

In a report issued on November 2, William Blair also maintained a Buy rating on the stock with a $97 price target.